AlphaCore Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

AlphaCore Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$953K	Sell	6,024 -1,298	-18%	-$175K	0.02%	480
2026 Q1	$935K	Sell	7,322 -328	-4%	-$40.9K	0.02%	403
2025 Q4	$933K	Buy	7,650 +7,210	+1,639%	+$827K	0.02%	436
2025 Q3	$44.1K	Sell	440 -100	-19%	-$9.01K	﹤0.01%	883
2025 Q2	$44.8K	Buy	540 +532	+6,650%	+$42.4K	﹤0.01%	825
2025 Q1	$675	Buy	+8	New	+$715	﹤0.01%	764
2024 Q1	–	Sell	-1,429	Closed	-$128K	–	392
2023 Q4	$128K	Buy	+1,429	New	+$106K	0.02%	240
2023 Q3	–	Sell	-100	Closed	-$8.32K	–	383
2023 Q2	$8.32K	Hold	100	–	–	﹤0.01%	305
2023 Q1	$7.62K	Buy	+100	New	+$8.3K	﹤0.01%	205
2021 Q4	–	Sell	-200	Closed	-$25K	–	135
2021 Q3	$25K	Buy	+200	New	+$25.8K	0.01%	93

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

AlphaCore Capital's XBI Position: Q2 2026 in Review

AlphaCore Capital reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 18% in Q2 2026, selling an estimated $175K and leaving 6,024 shares worth $953K. The position accounts for 0.02% of the portfolio, ranked #480.

AlphaCore Capital first reported a position in XBI in Q3 2021 and has held it in 10 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

AlphaCore Capital held 6,024 shares of State Street SPDR S&P Biotech ETF worth $953K as of Q2 2026.
AlphaCore Capital sold 1,298 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $175K.
State Street SPDR S&P Biotech ETF made up 0.02% of AlphaCore Capital's portfolio in Q2 2026, its #480 holding.
AlphaCore Capital first reported a position in State Street SPDR S&P Biotech ETF in Q3 2021 and has held it in 10 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.